Medy Tox (Korea) Top Management

086900 Stock  KRW 128,800  1,600  1.26%   
Medy Tox employs about 577 people. The company is managed by 7 executives with a total tenure of roughly 1347 years, averaging almost 192.0 years of service per executive, having 82.43 employees per reported executive. Analysis of Medy Tox's management performance can provide insight into the company performance.
HeeSeok Joo  Insider
Managing Division
SeungBum Park  Insider
Head Director
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Medy Tox. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Medy Tox Management Team Effectiveness

The company has return on total asset (ROA) of 0.0304 % which means that it generated a profit of $0.0304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.053 %, meaning that it generated $0.053 on every $100 dollars invested by stockholders. Medy Tox's management efficiency ratios could be used to measure how well Medy Tox manages its routine affairs as well as how well it operates its assets and liabilities.

Medy Tox Workforce Comparison

Medy Tox is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 3,906. Medy Tox retains roughly 577 in number of employees claiming about 15% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.16 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.16.

Medy Tox Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Medy Tox Price Series Summation is a cross summation of Medy Tox price series and its benchmark/peer.

Medy Tox Notable Stakeholders

A Medy Tox stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Medy Tox often face trade-offs trying to please all of them. Medy Tox's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Medy Tox's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
HeeSeok JooManaging DivisionProfile
SeungBum ParkHead DirectorProfile
HyunHo JungCEO DirectorProfile
YongIn KimManaging DevelProfile
KiHyuk YangMD LaboratoryProfile
Lopez MichaelManaging OfficeProfile
WooSun LeeDirector DepartmentProfile

About Medy Tox Management Performance

The success or failure of an entity such as Medy Tox often depends on how effective the management is. Medy Tox management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Medy management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Medy management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Medy-Tox Inc., a biopharmaceutical company, develops, manufactures, markets, and sells botulinum toxin and hyaluronic acid dermal filler products primarily in South Korea. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea. MedyTox is traded on Korean Securities Dealers Automated Quotations in South Korea.
Please note, the presentation of Medy Tox's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Medy Tox's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Medy Tox's management manipulating its earnings.

Medy Tox Workforce Analysis

Traditionally, organizations such as Medy Tox use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Medy Tox within its industry.

Medy Tox Manpower Efficiency

Return on Medy Tox Manpower

Revenue Per Employee320.4M
Revenue Per Executive26.4B
Net Income Per Employee163.2M
Net Income Per Executive13.5B
Working Capital Per Employee65.9M
Working Capital Per Executive5.4B

Complementary Tools for Medy Stock analysis

When running Medy Tox's price analysis, check to measure Medy Tox's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medy Tox is operating at the current time. Most of Medy Tox's value examination focuses on studying past and present price action to predict the probability of Medy Tox's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medy Tox's price. Additionally, you may evaluate how the addition of Medy Tox to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.